Key result
Epicardial pacing using a novel miniaturized pacemaker successfully manages CAVB in extremely premature neonates.
Why the study?
Congenital complete atrioventricular block carries a guarded prognosis, particularly when associated with extreme prematurity and severe bradycardia, prompting the use of novel pediatric pacing technologies.
Case Report (n=2)
Epicardial pacing using a novel miniaturized pacemaker is a feasible management strategy for congenital complete atrioventricular block in extremely premature neonates.
Case reports support pacing feasibility in extreme-prematurity CCAVB; leaves open optimal strategies and long-term outcomes.
Congenital complete atrioventricular block (CCAVB) is a rare autoimmune mediated disorder with a guarded prognosis, particularly when associated with extreme prematurity and severe bradycardia. Recent advances in neonatal care for extremely premature infants with delivery at level IV neonatal intensive care unit and novel pediatric pacing technologies, have significantly reduced morbidity and mortality in this unique patient population. We present 2 cases of CCAVB in extremely premature neonates, who were successfully managed with epicardial pacing using a novel miniaturized pacemaker.
No takes yet. Share an insight, caveat, or question.
Kalithkar et al. (2026) conducted a case report in Congenital complete atrioventricular block (CCAVB) (n=2). Epicardial pacing using a novel miniaturized pacemaker was evaluated. Epicardial pacing using a novel miniaturized pacemaker successfully managed congenital complete atrioventricular block in 2 extremely premature neonates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: